Detection of circulating tumor cells in patients with breast cancer using the quantitative RT-PCR assay for monitoring of therapy efficacy

Experimental and Molecular Pathology

Volumn 97, Issue 3, 2014, Pages 445-452

  Wang, Hye Young ^a   Ahn, Sungwoo ^b   Kim, Sunghyun ^b,c   Park, Sunyoung ^b   Park, Sangjung ^e   Han, Hyunju ^f   Sohn, Joo Hyuk ^g   Kim, SeungIl ^d   Lee, Hyeyoung ^c  

^a Wonju Eco Environmental Technology Center   (South Korea)

^b Yonsei University Wonju   (South Korea)

^c Yonsei University   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Daegu Haany University   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

^g Yonsei University College of Medicine   (South Korea)

Author keywords

Anti tumor treatment; Breast cancer; Circulating tumor cells (CTCs); Molecular diagnosis; Quantitative real time PCR (RT qPCR)

Indexed keywords

ANDROGEN RECEPTOR; COMPLEMENTARY DNA; CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; ESTROGEN RECEPTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TELOMERASE REVERSE TRANSCRIPTASE; TRASTUZUMAB; VIMENTIN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DISEASE MARKER; DNA SYNTHESIS; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; MOLECULAR DIAGNOSIS; PATIENT MONITORING; PREDICTIVE VALUE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA DEGRADATION; YOUNG ADULT; AGED; BLOOD; BREAST NEOPLASMS; DRUG EFFECTS; MASTECTOMY; PATHOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; TUMOR EMBOLISM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84908106231     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2014.09.003     Document Type: Article

References (22)

1. Alunni-Fabbroni M., et al. Circulating tumour cells in clinical practice: methods of detection and possible characterization. Methods 2010, 50:289-297.
2. Amadori A., et al. Circulating and disseminated tumor cells in the clinical management of breast cancer patients: unanswered questions. Oncology 2009, 76:375-386.
3. Andreopoulou E., et al. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus VeridexCellSearch™ system. Int. J. Cancer 2012, 130:1590-1597.
4. Benson J.R., et al. The global breast cancer burden. Future Oncol. 2012, 8:697-702.
5. Breast Cancer Statistics Available online:, (accessed on 23 May 2013). http://www.cancerresearchuk.org/.
6. Domagala W., et al. Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas. Am. J. Pathol. 1990, 137:1299-1304.
7. Elder E.E., et al. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma. Mod. Pathol. 2003, 16:246-255.
8. Fass L. Imaging and cancer: a review. Mol. Oncol. 2008, 2:115-152.
9. Fehm T., et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res. Treat. 2010, 124:403-412.
10. Ignatiadis M., et al. Circulating tumor cells in breast cancer. Curr. Opin. Obstet. Gynecol. 2008, 20:55-60.
11. Ignatiadis M., et al. Micrometastatic disease in breast cancer: clinical implications. Eur. J. Cancer 2008, 44:2726-2736.
12. Moretti E., et al. TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer. Futur. Oncol. 2013, 1(9):1477-1487.
13. Müller V., et al. Prognostic impact of circulating tumor cells assessed with the Cell Search System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Res. 2012, 14:R118.
14. Ntoulia M., et al. HER-2 DNAquantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistryand chromogenic in situ hybridization. Clin. Biol. Chem. 2006, 39:942-946.
15. Radhika K., et al. Estrogen and progesterone hormone receptor status in breast carcinoma: comparison of immunocytochemistry and immunohistochemistry. Indian J. Cancer 2010, 47:148-150.
16. Raimondi C., et al. Clinical utility of circulating tumor cell counting through Cell Search(®): the dilemma of a concept suspended in Limbo. Onco Targets Ther. 2014, 7:619-625.
17. Riethdorf S., Fritsche, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search System. Clin. Cancer Res. 2007, 13:920-928.
18. Slade M.J., et al. The clinical significance of disseminated tumor cells in breast cancer. Nat. Clin. Pract. Oncol. 2007, 4:30-41.
19. Swennenhuis J.F., et al. Efficiency of whole genome amplification of single circulating tumor cells enriched by Cell Search and sorted by FACS. Genome Med. 2013, 5:106.
20. Tan P.H., et al. Cytokeratins inpapillary lesions of the breast: is there a role indistinguishing intraductal papilloma from papillaryductal carcinoma in situ?. Am. J. Surg. Pathol. 2005, 29:625-632.
21. Van der Auwera I., et al. Circulating tumour cell detection: a direct comparison between the Cell Search System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br. J. Cancer 2010, 102:276-284.
22. Zidan J., et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br. J. Cancer 2005, 93:552-556.